Ms. Clancy joined Kura with more than 20 years of experience in the biotechnology and pharmaceutical industry leading global drug development from preclinical through commercial launch, as well as lifecycle management. Most recently, she was Head of Program, Project and Portfolio Management at Endo Pharmaceuticals, where she instituted a new operating model empowering high-performing talent and ensuring integrated delivery through others. She led an innovative first-to-market biologic through Phase 2 and 3 to biologics license application (BLA) submission, advisory committee prep, and planning for approval and launch as a cross-functional program leader. Prior, she facilitated the divestiture of GSK’s marketed oncology portfolio and late-phase clinical assets to Novartis. Previously, she held various R&D leadership roles at AstraZeneca in early- and late-stage development, portfolio initiatives and oversight of an oncology subsidiary. She began her career as a chemist at Merck. Ms. Clancy earned her executive MBA from Temple University, additional executive education at Wharton, University of Pennsylvania and her B.S. in chemistry from Seton Hall University.